Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist

2001 ◽  
Vol 66 (3) ◽  
pp. 135-139 ◽  
Author(s):  
Tomoyasu Tsushima ◽  
Yasutomo Nasu ◽  
Takashi Saika ◽  
Yoshio Maki ◽  
Masatoshi Noda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gonadotropin Releasing Hormone ◽  
Disease Flare ◽  
Releasing Hormone ◽  
Starting Time ◽  
Gonadotropin Releasing Hormone Agonist

scholarly journals Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a)

1996 ◽  
Vol 42 (8) ◽  
pp. 1176-1181 ◽  
Author(s):  
L Denti ◽  
G Pasolini ◽  
P Cortellini ◽  
S Ferretti ◽  
L Sanfelici ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cluster Analysis ◽  
Gonadal Hormones ◽  
Gonadotropin Releasing Hormone ◽  
Cross Sectional ◽  
Releasing Hormone ◽  
Lipoprotein A ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Androgen Suppression ◽  
Clear Relation

Abstract No clear relation between lipoprotein(a) [Lp(a)] and endogenous gonadal hormones has been demonstrated. In this study, we compared the effects on Lp(a) of pharmacological castration in 50 patients with prostate cancer who were undergoing therapy with a gonadotropin-releasing hormone agonist (goserelin), with effects on 58 age-matched controls. We also studied 16 untreated patients under baseline conditions and after 3 months of therapy with goserelin alone or combined with an antiandrogen (flutamide). Neither cross-sectional nor prospective studies showed any significant effects of therapy on Lp(a). However, cluster analysis identified a subgroup of patients showing slight but significant increases in Lp(a) concentrations, as well as greater declines of testosterone and estradiol, suggesting that androgen, like estrogen, can exert some slight, though not easily detectable, influence on Lp(a).

Sign in / Sign up

Export Citation Format

Share Document